VA
ZNTL icon

Vident Advisory’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Vident Advisory’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-14,735
Closed -$44.6K – 1645
2024
Q4 		$44.6K Buy
+14,735
New +$48.3K ﹤0.01% 1426

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vident Advisory's ZNTL Position: Q1 2025 in Review

Vident Advisory sold out of Zentalis Pharmaceuticals (ZNTL) in Q1 2025, closing a stake of 14,735 shares — an estimated $44.6K sold.

Vident Advisory first reported a position in ZNTL in Q4 2024 and held it in 1 quarter. The position peaked at $44.6K in Q4 2024. 132 funds tracked by Wall St. Rank hold ZNTL as of Q1 2025.

  • Vident Advisory reported no remaining Zentalis Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Vident Advisory sold 14,735 Zentalis Pharmaceuticals shares in Q1 2025, an estimated $44.6K.
  • Vident Advisory first reported a position in Zentalis Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Vident Advisory's Zentalis Pharmaceuticals position peaked at $44.6K in Q4 2024.
  • 132 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2025.

Based on Vident Advisory's 13F filing for Q1 2025, filed 15 May 2025.